可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Yang W, Ahn H, Hinrichs M, et al. Evidence of a novel isoform of placenta growth factor (PGF4) expressed in human trophoblast and endothelial cells[J]. J Reprod Immunol, 2003, 60(1):53-60.
[2] 张海宏,张玉成,曾智. 胎盘生长因子与心血管疾病中的血管生成[J]. 心脏杂志, 2005, 17(6):610-612.
[3] Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia[J]. N Engl J Med, 2004, 350(7):672-683.
[4] Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and for preeclampsia[J]. J Clin Endocrinol Metab, 2004, 89(2):770-775.
[5] Cho GJ, Roh GS, Kim HJ, et al. Differential expression of placenta growth factors and their receptors in the normal and pregnancy induced hypertensive human placentas[J]. J Korean Med Sci, 2003, 18(3):402-408.
[6] Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation[J]. Blood, 2003, 101(2):560-567.
[7] Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerosis intimal thickening and macrophage accumulation[J]. Circulation, 2005, 111(21):2828-2836.
[8] Pilarczyk K, Sattler KJ, Galili O, et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization[J]. Atherosclerosis, 2008, 196(1):333-340.
[9] Iwama H, Uemura S, Naya N, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction[J]. J Am Coll Cardiol, 2006, 47(8):1559-1567.
[10]V S, Eggermann J, Dunaeva M, et al. Enhanced functional response of CD133+ circulating progenitor cells in patients early after acute myocardial infarction[J]. Eur Heart J, 2008, 29(2):241-250.
[11]Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain[J]. JAMA, 2004, 291(4):435-441.
[12]Lenderink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2006, 47(2):307-311.
[13]Apple FS, Pearce LA, Chung A, et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome[J]. Clin Chem, 2007, 53(5):874-881.
[14]Kolakowski S Jr, Berry MF, Atluri P, et al. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy[J]. J Card Surg, 2006, 21(6):559-564.
[15]Lambiase PD, Edwards RJ, Anthopoulos P, et al. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support[J]. Circulation, 2004, 109(24):2986-2992.
[16]Werner GS, Jandt E, Andreas K. Growth factors in the collateral circulation of chronic total coronary occlusions relation to duration of occlusion and collateral function[J]. Circulation, 2004, 110(14):1940-1945.
[17]Briguori C, Testa U, Colombo A, et al. Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals[J]. Am J Cardiol, 2006, 97(4):472-476.
[18]Kodama Y, Kitta Y, Nakamura T, et al. Atorvastatin increase plasma soluble Fms-like tyrosine kinase-1 and decrease vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction[J]. J Am Coll Cardiol, 2006, 48(1):43-50.
[19]Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1[J]. Nat Med, 2003, 9(7):936-943.